Avastin vs Lucentis Letter sent to Vice-President Almunia on March 17th, 2014 Contact: Ilaria Passarani – [removed] Ref.: BEUC-X[removed] 2014 - X Factor - Document - PDFSEARCH.IO

First Page		Document Content
Date: 2014-03-18 12:19:39 Bevacizumab Ranibizumab Angiology Macular degeneration Pharmaceutical industry Vascular endothelial growth factor Directorate-General for Health and Consumers Committee for Medicinal Products for Human Use Consumer organization Medicine Congress of Deputies Health		Avastin vs Lucentis Letter sent to Vice-President Almunia on March 17th, 2014 Contact: Ilaria Passarani – [removed] Ref.: BEUC-X[removed]/2014 Add to Reading List Source URL: www.beuc.org Download Document from Source Website File Size: 266,81 KB Share Document on Facebook

	Strictly embargoed for 00.01hrs, Friday 20 November New target for macular degeneration gets funding for clinical trials The Medical Research Council is to fund researchers at the UCL Institute of Ophthalmology and Moor DocID: 1tWX0 - View Document
	November 25, 2015 Foundation for Biomedical Research and Innovation RIKEN Kobe City Medical Center General Hospital Termination of subject enrollment for the “Clinical study of autologous induced pluripotent stem cell- DocID: 1rstZ - View Document
	What is OCT and what can you do with OCT? Introduction For most people, the severe vision loss of visual acuity or blindness are the worst imaginable fate that often more feared than cancer or death. But for most patient DocID: 1rmdW - View Document
	October 9, 2015 (Initially issued in Japanese on October 2, 2015) Foundation for Biomedical Research and Innovation (FBRI) RIKEN Kobe City Medical Center General Hospital Update on first transplant recipient in the “Cl DocID: 1rm8x - View Document
	2016 Pathways to Cures: Clinical Translational Research Day at UCI ORAL PRESENTATIONS 4:00 pm – 5:00 pm Pacific Ballroom D Session moderated by Dr. Michael Stamos DocID: 1r4Al - View Document